Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

January 7, 2024

https://www.globenewswire.com/news-release/2024/01/07/2805008/0/en/Caribou-Biosciences-Appoints-Tim-Kelly-as-Chief-Technology-Officer-and-Highlights-Multiple-Clinical-Catalysts-Expected-in-2024.html

— Tim Kelly to lead Caribou’s technical operations strategy and execution —

— CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 —

Read more at globenewswire.com

Related news for (CRBU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.